Phaarmasia Ltd (PHRMASI) — shareholding pattern, promoter holding, financials and share price
About Phaarmasia Ltd (PHRMASI)
Phaarmasia Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as PHRMASI and on the BSE under scrip code 523620. Its ISIN is INE486I01016.
Incorporated in 1981, Phaarmasia Ltd is engaged in manufacturing and marketing of Cosmetics, Oral Contraceptive Pills (OCP) and Combipack with Iron Tablets
Phaarmasia Limited, established in 1981, specializes in manufacturing and marketing oral contraceptive tablets and iron tablets, primarily serving the Ministry of Health & Family Welfare and export markets.
The company boasts a state-of-the-art manufacturing facility with a capacity exceeding 30 million units annually, meeting WHO-GMP and ISO 9001 certification standards.
Listed peers in Pharmaceuticals: Source Natural Foods & Herbal Supplements Ltd, Vilin Bio Med Ltd, Onyx Biotec Ltd, Asston Pharmaceuticals Ltd, Ajooni Biotech Ltd, Vineet Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹95.52 a share on 10 Jul 2026, Phaarmasia Ltd (PHRMASI) was valued at a price-to-earnings ratio of 3.71x against an industry P/E of 36.41x and a price-to-book of 7.46x on a book value of ₹12.8 per share as of Mar 2025. Solomo computes return on equity of 201.24% and return on capital employed of 247.07% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 3.71x
- Industry P/E
- 36.41x
- P/B
- 7.46x
- EPS (TTM)
- ₹25.75
- Book value / share
- ₹12.8
- ROE
- 201.24%
- ROCE
- 247.07%
- ROA
- 81.54%
- Debt / equity
- 0x
- Dividend yield
- 0%
- EBITDA margin
- 46.23%
- 52-week range
- ₹95.52 – ₹100.37
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Phaarmasia Ltd (PHRMASI) reported revenue of ₹47 crore, net profit of ₹18 crore and earnings per share of ₹25.74. That compares with revenue of ₹24 crore and net profit of ₹-2 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹7.73 crore and net profit ₹-0.7 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 17 | 27 | 31 | 24 | 47 |
| Net profit (₹ cr) | -2 | -1 | -1 | -2 | 18 |
| EPS (₹) | -2.27 | -1.85 | -0.76 | -2.33 | 25.74 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 1.35% | -0.07% | 12.28% | -20.33% |
| Profit growth | - | - | - | -205.77% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 73.51% of Phaarmasia Ltd (PHRMASI) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 0.06%. Market capitalisation was ₹65 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: SHUBHADA GODAMBE ATUL 1.73%, MADHAVI PRADEEP SAVE 1.73%, KALPANA PATANKAR 1.65%, AMRUTA NISHANT KALSEKAR 1.49%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 73.51% | - | - | 0.06% | 26.49% |
| Mar 2026 | 73.51% | - | - | 0.06% | 26.49% |
| Dec 2025 | 73.51% | - | 0% | 0.05% | 26.49% |
| Sep 2025 | 73.51% | - | - | 0.06% | 26.49% |
| Jun 2025 | 73.51% | - | - | 0.06% | 26.49% |
| Mar 2025 | 73.51% | - | - | 0.06% | 26.49% |
| Dec 2024 | 73.51% | - | - | 0.06% | 26.49% |
| Sep 2024 | 73.51% | - | - | 0.06% | 26.49% |